Back HIV/AIDS

HIV / AIDS

IAS 2013: Women Who Start Option B+ ART During Pregnancy Often Lost to Follow-up

Women who begin HIV treatment during pregnancy or while breastfeeding, prior to the CD4 cell threshold previously recommended for starting treatment (350 cells/mm3), were significantly more likely to be lost to follow-up than women who started treatment at the general treatment threshold, Malawian researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

IAS 2013: End-Stage Kidney Disease Is More Common Among People with HIV

HIV positive people in the U.S. and Canada are nearly 4 times as likely to develop end-stage renal disease than HIV negative people in the general population, largely driven by a very high rate among blacks, researchers reported last month at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

IAS 2013: Single Tablet Regimens Do Not Always Produce Better HIV Treatment Outcomes

One pill per day does not necessarily lead to more durable HIV suppression than regimens containing more pills taken twice-daily, according to a study presented at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

IAS 2013: Life Expectancy of HIV+ People in North America Increased by 15 Years

A 20-year-old HIV positive person on effective antiretroviral therapy (ART) in the U.S. or Canada has a remaining life expectancy of about 50 years, approaching that of HIV negative individuals, according to a poster presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last month in Kuala Lumpur.

alt

IAS 2013: Combination Prevention Trial Shows Drop in HIV Incidence, Increase in Testing

Results from Project ACCEPT, a pioneering HIV prevention trial comparing the effects of mobile HIV testing, community mobilization, and enhanced support for people with HIV, versus standard voluntary counseling and testing, were announced at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lumpur.

alt

IAS 2013: Raltegravir/Etravirine Dual Regimen Maintains Viral Suppression

A regimen of raltegravir (Isentress) plus etravirine (Intelence) without NRTIs or protease inhibitors was able to keep HIV in check after switching from a standard regimen if patients did not have pre-existing NNRTI resistance, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

FDA Limits Use of Oral Antifungal Ketoconazole Due to Side Effects and Drug Interactions

The antifungal drug ketoconazole (brand name Nizoral), used to treat certain AIDS-related opportunistic infections, should no longer be used as first-line oral therapy for any infection due to its potential to cause liver toxicity and adrenal gland problems, and instead should be reserved for those who cannot take or do not respond to other treatments, according to the U.S. Food and Drug Administration. The warning does not apply to topical formulations.

alt